Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome

Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome

Tisagenlecleucel (tisa-cel) is a CD19-specific CAR-T cell product approved for the treatment of relapsed/refractory (r/r) DLBCL or B-ALL. We have followed a group of patients diagnosed with childhood B-ALL (n = 5), adult B-ALL (n = 2), and DLBCL (n = 25) who were treated with tisa-cel under non-clin...

Full description

Bibliographic Details
Main Authors: Martin Štach, Robert Pytlík, Kristýna Šmilauerová, Jana Rychlá, Martin Mucha, Jan Musil, Abhishek Koladiya, Matěj Nemec, Martina Petráčková, Iva Kaštánková, Pavla Pecherková, Lucie Šrámková, Kamila Polgárová, Marek Trněný, Petr Lesný, Jan Vydra, Pavel Otáhal
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Pathology and Oncology Research
Subjects:
immunotherapy
CAR-T cells
tisagenlecleucel
B-cell lymphoma and leukemia
Kymriah
Online Access:https://www.por-journal.com/articles/10.3389/pore.2023.1610914/full

Internet

https://www.por-journal.com/articles/10.3389/pore.2023.1610914/full

Similar Items